Company: RCUS
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001724521-25-000052
Chunk: 39

Company: Arcus Biosciences, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 39
---
 includes 8,553 shares of common stock held by trusts.

(10) Consists of the number of shares of common stock beneficially owned by all executive officers and directors as of March 1, 2025.

<div align='center'>21.</div>

### EXECUTIVE OFFICERS
The following table sets forth information regarding our executive officers as of April 1, 2025:

| NAME                        |     | AGE |     | POSITION HELD WITH THE COMPANY                 |
| Terry Rosen, Ph.D.          |     |  66 |     | Chief Executive Officer, Director and Chairman |
| Robert C. Goeltz, II        |     |  52 |     | Chief Financial Officer                        |
| Juan Carlos Jaen, Ph.D.     |     |  67 |     | President                                      |
| Jennifer Jarrett            |     |  54 |     | Chief Operating Officer                        |
| Richard Markus, M.D., Ph.D. |     |  59 |     | Chief Medical Officer                          |
| Carolyn Tang                |     |  46 |     | General Counsel                                |

For a biography of Dr. Rosen, see “Proposal 1 – Election of Directors.”

Robert C. Goeltz II has served as our Chief Financial Officer since August 2020. Mr. Goeltz joined us from UNITY Biotechnology, Inc. (Nasdaq: UBX), a healthcare company focused on age-associated diseases, where he served as Chief Financial Officer and Senior Vice President from September 2017 to July 2020, in which position he was responsible for investor and public relations, accounting, financial planning and analysis, information systems, real estate, insurance, procurement and facilities. Prior to Unity, Mr. Goeltz was Chief Financial Officer and Senior Vice President at CytomX Therapeutics, Inc. (Nasdaq: CTMX), a biotechnology company focused on cancer therapeutics, from May 2015 to May 2017, in which position he was responsible for investor relations, finance, real estate, insurance, procurement, facilities and information systems. Prior to that, Mr. Goeltz served as Chief Financial Officer of Onyx Pharmaceuticals, Inc. after its acquisition by Amgen Inc., from October 2013 until May 2015. Previously, Mr. Goeltz held roles of increasing responsibility at Amgen Inc., including in Business Development, Commercial Finance, R&D Finance and Corporate Accounting from 2004 to 2013